AstraZeneca inks $555 million deal with Algen
UK pharma major AstraZeneca (LSE: AZN) has entered into a multi-target partnership with Algen Biotechnologies, the California, USA biotech announced.
Algen, spun out of Nobel Laureate Jennifer Doudna’s lab at the University of California, is pioneering next-generation therapies using advanced CRISPR gene modulation and AI-driven drug discovery, and the deal with AstraZeneca is aimed at accelerating the discovery of novel therapeutic targets in immunology.
Under the agreement, Algen will leverage its AlgenBrain platform to drive pre-clinical drug discovery, with AstraZeneca receiving exclusive rights to develop and commercialize therapies against a defined set of targets identified and selected through the partnership.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze